Tevogen Bio Holdings Inc.
TVGN
$6.97
-$0.03-0.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -54.77% | -7.29% | -38.66% | -17.73% | 574.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.76% | -5.85% | -36.68% | -64.91% | 365.99% |
| Operating Income | 50.76% | 5.85% | 36.68% | 64.91% | -365.99% |
| Income Before Tax | 50.47% | 2.67% | 43.04% | -192.03% | -160.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 50.47% | 2.67% | 43.04% | -192.03% | -160.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.47% | 2.67% | 43.04% | -192.03% | -160.02% |
| EBIT | 50.76% | 5.85% | 36.68% | 64.91% | -365.99% |
| EBITDA | 51.17% | 5.23% | 37.45% | 65.00% | -374.39% |
| EPS Basic | 46.81% | 13.88% | 22.33% | -185.06% | 39.90% |
| Normalized Basic EPS | 48.55% | 15.51% | 52.36% | 70.30% | 5.83% |
| EPS Diluted | 46.81% | 13.88% | 23.48% | 73.10% | 39.90% |
| Normalized Diluted EPS | 48.55% | 15.51% | 52.36% | 69.21% | 5.83% |
| Average Basic Shares Outstanding | -3.74% | 15.19% | 19.55% | 17.53% | 331.07% |
| Average Diluted Shares Outstanding | -3.74% | 15.19% | 19.55% | 13.35% | 331.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |